Comments on: Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens

Comments on: Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens https://www.novumpr.nl/2016/10/24/gilead-presents-results-from-phase-3-studies-evaluating-switching-to-descovy-ftctaf-based-regimens-from-truvada-ftctdf-based-regimens/?utm_source=rss&utm_medium=rss&utm_campaign=gilead-presents-results-from-phase-3-studies-evaluating-switching-to-descovy-ftctaf-based-regimens-from-truvada-ftctdf-based-regimens NovumPR press releases Mon, 24 Oct 2016 10:49:03 +0000 hourly 1 https://wordpress.org/?v=6.8.2